{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:05:53Z","timestamp":1781766353590,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Biogen China"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12325-024-03101-7","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T08:05:49Z","timestamp":1739779549000},"page":"1611-1626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Motor Function and Safety of Nusinersen and Risdiplam in Asian Patients with Types 2\u20134 Spinal Muscular Atrophy (SMA): A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Xinran","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2164-9266","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"issue":"1","key":"3101_CR1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","volume":"16","author":"G Coratti","year":"2021","unstructured":"Coratti G, et al. Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis. Orphanet J Rare Dis. 2021;16(1):430.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3101_CR2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"15","key":"3101_CR3","doi-asserted-by":"crossref","first-page":"11939","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, et al. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. Int J Mol Sci. 2023;24(15):11939.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"3101_CR4","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s40265-020-01410-z","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Risdiplam: first approval. Drugs. 2020;80(17):1853\u20138.","journal-title":"Drugs"},{"issue":"4","key":"3101_CR5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM. Nusinersen: first global approval. Drugs. 2017;77(4):473\u20139.","journal-title":"Drugs"},{"key":"3101_CR6","unstructured":"Chang, M. Korea\u2019s 1st gene treatment for SMA Zolgensma gets insurance benefits. 2022; Available from: https:\/\/www.koreabiomed.com\/news\/articleView.html?idxno=14296."},{"issue":"9","key":"3101_CR7","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40263-022-00941-1","volume":"36","author":"HA Blair","year":"2022","unstructured":"Blair HA. Onasemnogene abeparvovec: a review in spinal muscular atrophy. CNS Drugs. 2022;36(9):995\u20131005.","journal-title":"CNS Drugs"},{"key":"3101_CR8","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88: 105906.","journal-title":"Int J Surg"},{"key":"3101_CR9","unstructured":"T, L., H. JPT, and D. JJ, Chapter 5: Collecting data. In Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023), L. T, H. JPT, and D. JJ, Editors. 2023: Cochrane."},{"key":"3101_CR10","unstructured":"Wells G et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021."},{"issue":"9","key":"3101_CR11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"3101_CR12","doi-asserted-by":"crossref","unstructured":"Cumpston M et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for systematic reviews of interventions. Cochrane Database Syst Rev 2019;10(10): ED000142.","DOI":"10.1002\/14651858.ED000142"},{"key":"3101_CR13","doi-asserted-by":"crossref","first-page":"1294405","DOI":"10.3389\/fped.2023.1294405","volume":"11","author":"L Chen","year":"2023","unstructured":"Chen L, et al. Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children. Front Pediatr. 2023;11:1294405.","journal-title":"Front Pediatr"},{"issue":"11","key":"3101_CR14","first-page":"1039","volume":"8","author":"M Gu","year":"2021","unstructured":"Gu M, Kong HH. Improvement in fine manual dexterity in children with spinal muscular atrophy Type 2 after nusinersen injection: a case series. Children (Basel). 2021;8(11):1039.","journal-title":"Children (Basel)"},{"issue":"2","key":"3101_CR15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.braindev.2022.10.006","volume":"45","author":"H Iwayama","year":"2023","unstructured":"Iwayama H, et al. Long-term efficacy of nusinersen and its evaluation in adolescent and adult patients with spinal muscular atrophy types 1 and 2. Brain Dev. 2023;45(2):110\u20136.","journal-title":"Brain Dev"},{"issue":"3","key":"3101_CR16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.braindev.2022.11.002","volume":"45","author":"Y Shimizu-Motohashi","year":"2023","unstructured":"Shimizu-Motohashi Y, et al. Muscle impairment in MRI affect variability in treatment response to nusinersen in patients with spinal muscular atrophy type 2 and 3: a retrospective cohort study. Brain Dev. 2023;45(3):161\u201370.","journal-title":"Brain Dev"},{"issue":"4","key":"3101_CR17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/mus.27950","volume":"68","author":"YJ Lee","year":"2023","unstructured":"Lee YJ, et al. Impact of nusinersen on the health-related quality of life and caregiver burden of patients with spinal muscular atrophy with symptom onset after age 6 months. Muscle Nerve. 2023;68(4):404\u201313.","journal-title":"Muscle Nerve"},{"issue":"4","key":"3101_CR18","first-page":"303","volume":"30","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, et al. Nusinersen treatment in spinal muscular atrophy: a case. Chin J Neuroimmunol Neuro. 2023;30(4):303\u20136.","journal-title":"Chin J Neuroimmunol Neuro"},{"issue":"8","key":"3101_CR19","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/ped.14510","volume":"63","author":"R Tanaka","year":"2021","unstructured":"Tanaka R, et al. Nusinersen improved respiratory function in spinal muscular atrophy type 2. Pediatr Int. 2021;63(8):973\u20134.","journal-title":"Pediatr Int"},{"issue":"1","key":"3101_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.braindev.2023.08.005","volume":"46","author":"M Funato","year":"2024","unstructured":"Funato M, et al. Later efficacy of nusinersen treatment in adult patients with spinal muscular atrophy: a retrospective case study with a median 4-year follow-up. Brain Dev. 2024;46(1):62\u20137.","journal-title":"Brain Dev"},{"issue":"7","key":"3101_CR21","first-page":"688","volume":"60","author":"SS Mao","year":"2022","unstructured":"Mao SS, et al. Clinical follow-up analysis of nusinersen in the disease-modifying treatment of pediatric spinal muscular atrophy. Zhonghua Er Ke Za Zhi. 2022;60(7):688\u201393.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"1","key":"3101_CR22","volume":"100","author":"JM Park","year":"2021","unstructured":"Park JM, et al. Effect of Nusinersen in a late onset spinal muscular atrophy patient for 14 months: a case report. Medicine (Baltimore). 2021;100(1): e24236.","journal-title":"Medicine (Baltimore)"},{"key":"3101_CR23","doi-asserted-by":"publisher","unstructured":"Tachibana Y et al. Safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 524 patients: results from an interim analysis of post-marketing surveillance in Japan. Int J Neurosci 2023: https:\/\/doi.org\/10.1080\/00207454.2023.2251662.","DOI":"10.1080\/00207454.2023.2251662"},{"issue":"2","key":"3101_CR24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/00207454.2022.2095270","volume":"134","author":"Y Tachibana","year":"2024","unstructured":"Tachibana Y, et al. Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance. Int J Neurosci. 2024;134(2):153\u201362.","journal-title":"Int J Neurosci"},{"issue":"8","key":"3101_CR25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/00207454.2021.1995382","volume":"133","author":"T Wataya","year":"2023","unstructured":"Wataya T, et al. Real-world safety of nusinersen in Japan: results from an interim analysis of a post-marketing surveillance and safety database. Int J Neurosci. 2023;133(8):851\u201363.","journal-title":"Int J Neurosci"},{"issue":"1","key":"3101_CR26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12883-023-03063-3","volume":"23","author":"H Yang","year":"2023","unstructured":"Yang H, et al. Assessment of motor function and nutritional status in children with spinal muscular atrophy treated with nusinersen after loading period in Western China: a retrospective study. BMC Neurol. 2023;23(1):35.","journal-title":"BMC Neurol"},{"key":"3101_CR27","first-page":"47","volume":"11","author":"H Wang","year":"2023","unstructured":"Wang H, et al. Efficacy of nusinersen sodium injection in the treatment of children with spinal muscular atrophy. J Pediat Pharm. 2023;11:47\u20139.","journal-title":"J Pediat Pharm"},{"key":"3101_CR28","unstructured":"Wang B. Efficacy evaluation of nusinersen in 29 adolescents and adults with spinal muscular atrophy: a real-world cohort study. Shandong University. 2023."},{"issue":"3","key":"3101_CR29","first-page":"204","volume":"57","author":"Q Shao","year":"2023","unstructured":"Shao Q, et al. Clinical practice of nusinersen in the treatment of spinal muscular atrophy in children. J Fujian Med Univer. 2023;57(3):204\u201310.","journal-title":"J Fujian Med Univer"},{"issue":"4","key":"3101_CR30","first-page":"286","volume":"18","author":"K Ma","year":"2023","unstructured":"Ma K, et al. Nusinersen treatment in 68 children with 5q spinal muscular atrophy: a case series report. Chin J Evid Based Pediatr. 2023;18(4):286\u201390.","journal-title":"Chin J Evid Based Pediatr"},{"key":"3101_CR31","doi-asserted-by":"crossref","first-page":"1294028","DOI":"10.3389\/fneur.2023.1294028","volume":"14","author":"J Cho","year":"2023","unstructured":"Cho J, et al. Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea. Front Neurol. 2023;14:1294028.","journal-title":"Front Neurol"},{"issue":"6","key":"3101_CR32","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4103\/aian.AIAN_524_20","volume":"23","author":"AR Kim","year":"2020","unstructured":"Kim AR, et al. Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: a retrospective study. Ann Indian Acad Neurol. 2020;23(6):796\u2013801.","journal-title":"Ann Indian Acad Neurol"},{"issue":"5","key":"3101_CR33","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s12519-022-00638-x","volume":"19","author":"HJ Shin","year":"2023","unstructured":"Shin HJ, et al. Nusinersen for spinal muscular atrophy types II and III: a retrospective single-center study in South Korea. World J Pediatr. 2023;19(5):450\u20139.","journal-title":"World J Pediatr"},{"issue":"8","key":"3101_CR34","first-page":"1161","volume":"54","author":"W Liu","year":"2023","unstructured":"Liu W, et al. Clinical analysis of risdiplam in the treatment of spinal muscular atrophy in children. J Shanxi Med Univer. 2023;54(8):1161\u20134.","journal-title":"J Shanxi Med Univer"},{"issue":"19","key":"3101_CR35","first-page":"2414","volume":"34","author":"Z Shi","year":"2023","unstructured":"Shi Z, et al. Study on the value of pharmaceutical service related to risdiplam based on follow-up data of DTP pharmacy. China Pharm. 2023;34(19):2414\u20138.","journal-title":"China Pharm"},{"issue":"6","key":"3101_CR36","first-page":"944","volume":"44","author":"Y Chen","year":"2023","unstructured":"Chen Y, et al. Nusinersen treatment in patients with spinal muscular atrophy: a safety analysis of laboratory parameters. J Xi\u2019an Jiaotong Univer Med Sci. 2023;44(6):944\u20139.","journal-title":"J Xi\u2019an Jiaotong Univer Med Sci"},{"issue":"6","key":"3101_CR37","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.nmd.2022.04.003","volume":"32","author":"Y Fainmesser","year":"2022","unstructured":"Fainmesser Y, et al. Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3. Neuromuscul Disord. 2022;32(6):451\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"3101_CR38","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/ped.13867","volume":"61","author":"M Sugimoto","year":"2019","unstructured":"Sugimoto M, et al. Nusinersen helps restore walking ability in childhood spinal muscular atrophy. Pediatr Int. 2019;61(7):728\u20139.","journal-title":"Pediatr Int"},{"issue":"7","key":"3101_CR39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"key":"3101_CR40","doi-asserted-by":"crossref","unstructured":"Oskoui M, Darras BT, De Vivo DC. Spinal muscular atrophy. Disease mechanisms and therapy. 2017.","DOI":"10.1016\/B978-0-12-803685-3.00001-X"},{"issue":"2","key":"3101_CR41","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s13311-022-01200-3","volume":"19","author":"M Gavriilaki","year":"2022","unstructured":"Gavriilaki M, et al. Nusinersen in adults with 5q spinal muscular atrophy: a systematic review and meta-analysis. Neurotherapeutics. 2022;19(2):464\u201375.","journal-title":"Neurotherapeutics"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03101-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:08:56Z","timestamp":1742713736000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03101-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3101"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03101-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xinran Zhao, Yihan Liao, Jingyu Zhao and Jun Liu are employees of IQVIA, Real-World Solutions, China, which received consulting fees from Biogen for conducting the literature review and meta-analysis. Lin Zhu is an employee of Biogen and may hold stock. Min Zhang, Wei Li and all other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}